Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by TNFSF15 is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. Additionally we are shipping TNFSF15 Antibodies (129) and TNFSF15 Kits (9) and many more products for this protein.
Showing 10 out of 34 products:
Human TNFSF15 Protein expressed in Escherichia coli (E. coli) - ABIN2666725
Aiba, Nakamura: The role of TL1A and DR3 in autoimmune and inflammatory diseases. in Mediators of inflammation 2014
Show all 6 references for ABIN2666725
Human TNFSF15 Protein expressed in Escherichia coli (E. coli) - ABIN666796
Zhai, Ni, Jiang, Lu, Xing, Lincoln, Carter, Janat, Kozak, Xu, Rojas, Aggarwal, Ruben, Li, Gentz, Yu: VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. in FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1999
Show all 2 references for ABIN666796
Rat (Rattus) TNFSF15 Protein expressed in Human Cells - ABIN3216410
Prehn, Thomas, Landers, Yu, Michelsen, Targan: The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. in Journal of immunology (Baltimore, Md. : 1950) 2007
Higher TL1A levels were associated with early stage chronic lymphocytic leukemia.
TL1A-induced cell death is directly mediated through DR3 (show TNFRSF25 Proteins).
Plasma levels of TL1A were significantly higher in newly diagnosed SLE patients compared with controls, and were positively associated with SLE disease activity index.
This study indicates that the HDAC (show HDAC3 Proteins) inhibitor may be exploited as a therapeutic strategy modulating the soluble VEGI/DR3 (show TNFRSF25 Proteins) pathway in osteosarcoma patients
Results show that subjects with TNFSF15 -358CC genotype were at higher risks for developing gastric adenocarcinoma in the Helicobacter pylori infected group.
The data indicate that TL1A may contribute to pathogenesis of inflammatory bowel diseases via local but not systemic induction of IL-17A (show IL17A Proteins) but not IL-4 (show IL4 Proteins), IL-13 (show IL13 Proteins) or IFN-gamma (show IFNG Proteins).
study has defined the increased serum and SF samples levels of TL1A and DcR3 (show TNFRSF6B Proteins) in patients with rheumatoid arthritis (RA); findings support the hypothesis that TL1A and DcR3 (show TNFRSF6B Proteins) may contribute to the pathogenesis of RA
TNFSF15 SNPs, rs6478108 and rs4574921, may be independent genetic predictive factors for the development of stricture/non-perianal penetrating complications and perianal fistula, respectively.
TL1A increases expression of CD25 (show IL2RA Proteins), LFA-1 (show ITGAL Proteins), CD134 (show TNFRSF4 Proteins) and CD154 (show CD40LG Proteins), and induces IL-22 (show IL22 Proteins) and GM-CSF (show CSF2 Proteins) production from effector CD4 (show CD4 Proteins) T-cells
Addition of TL1A to IL-1beta (show IL1B Proteins) + IL-23 (show IL23A Proteins) also augmented ILC3 proliferation
These data demonstrated a direct role for TL1A-DR3 (show TNFRSF25 Proteins) signaling in tissue fibrosis and that modulation of TL1A-DR3 (show TNFRSF25 Proteins) signaling could inhibit gut (show GUSB Proteins) fibrosis.
these data identify TL1A-DR3 (show TNFRSF25 Proteins) interactions as a novel pathway that promotes Th9 differentiation and pathogenicity. TL1A may be a potential therapeutic target in diseases dependent on IL-9 (show IL9 Proteins).
TL1A induces NF-kappaB (show NFKB1 Proteins) activation in EC in renal and cardiac tissue from wild type but not DR3 (show TNFRSF25 Proteins) knock-out mice.
TL1A deficiency impacts on the gut (show GUSB Proteins) microbial composition and the mucosal immune system, especially the intraepithelial TCRgammadelta(+) T-cell subset, and that TL1A is involved in the establishment of adipose tissue.
Our data demonstrate a key role for TL1A in promoting ILC2s at mucosal barriers.
TNFSF15 inhibits vasculogenesis by regulating relative levels of membrane-bound and soluble isoforms of VEGF receptor (show FLT1 Proteins) 1.
Both in supernatant and as purified fusion protein, TL1A-Ig binds to TNFRSF25 (show TNFRSF25 Proteins) transfected--but not untransfected--P815 tumor cells as determined by flow cytometry.
These results establish a novel link between tumor necrosis factor (TNF (show TNF Proteins))-family cytokine TL1A (TNFSF15) and interleukin 13 (IL-13 (show IL13 Proteins)) responses that results in small intestinal inflammation.
role of TL1A in mucosal T cells and antigen presenting cells function and showed that up-regulation of TL1A expression can promote mucosal inflammation and gut (show GUSB Proteins) fibrosis.
findings suggest that the transcription factor NF-kappaB (show NFKB1 Proteins) plays an important role in the regulation of VEGI expression
The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein is abundantly expressed in endothelial cells, but is not expressed in either B or T cells. The expression of this protein is inducible by TNF and IL-1 alpha. This cytokine is a ligand for receptor TNFRSF25 and decoy receptor TNFRSF21/DR6. It can activate NF-kappaB and MAP kinases, and acts as an autocrine factor to induce apoptosis in endothelial cells. This cytokine is also found to inhibit endothelial cell proliferation, and thus may function as an angiogenesis inhibitor. Two transcript variants encoding different isoforms have been found for this gene.
tumor necrosis factor ligand superfamily member 15
, vascular endothelial growth inhibitor
, tocopherol (alpha) transfer protein-like
, TNF ligand-related molecule 1
, TNF superfamily ligand TL1A
, vascular endothelial cell growth inhibitor
, vascular endothelial growth inhibitor-192A
, bM20K13.3 (tumor necrosis factor (ligand) superfamily, member 15)